• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazole carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Pyrazole carboxylic acids and derivatives

Professional Introduction to 1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid (CAS No. 650603-96-6)

1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 650603-96-6, is a heterocyclic compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This bicyclic structure combines a cyclooctane ring with multiple pyrazole moieties, making it a versatile scaffold for drug discovery. The presence of a carboxylic acid functional group at the 3-position enhances its reactivity and potential for further derivatization, opening up avenues for the development of novel therapeutic agents.

The compound's unique structural features position it as a promising candidate for exploring various biological activities. Recent studies have highlighted the potential of cycloalkylpyrazole derivatives in modulating enzyme inhibition and receptor binding. Specifically, the rigid cyclooctane ring contributes to steric constraints that can improve binding affinity to target proteins, while the pyrazole rings provide hydrogen bonding opportunities and electronic properties conducive to drug-receptor interactions.

In the realm of drug design, 1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid has been investigated for its potential in addressing inflammatory and immunomodulatory disorders. Preliminary in vitro studies suggest that derivatives of this compound may exhibit inhibitory effects on key inflammatory pathways such as NF-κB and MAPK. The carboxylic acid moiety allows for facile conjugation with other pharmacophores or biomolecules, enabling the development of targeted therapies that could selectively modulate immune responses.

Moreover, the compound's stability under various physicochemical conditions makes it an attractive intermediate for synthetic chemistry. Researchers have leveraged its structural framework to explore novel synthetic pathways that could streamline the production of more complex derivatives. Advances in computational chemistry have further accelerated the design process by predicting optimal modifications to enhance bioactivity while maintaining solubility and metabolic stability.

The integration of 1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid into drug discovery pipelines aligns with current trends toward polypharmacophoric compounds—molecules capable of interacting with multiple targets simultaneously. Such multitarget engagement has been shown to improve therapeutic efficacy and reduce side effects by modulating complex disease mechanisms. The cyclooctacpyrazole scaffold provides a balanced platform for such multitarget strategies due to its ability to accommodate diverse functional groups while maintaining structural integrity.

Recent breakthroughs in crystal engineering have also shed light on the conformational flexibility of this compound. X-ray diffraction studies reveal that 1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid adopts multiple stable conformations in solid-state structures. These conformational polymorphs may influence solubility and pharmacokinetic properties when transitioning from laboratory settings to clinical applications. Understanding these structural variations is crucial for optimizing formulations and ensuring consistent drug performance across different environments.

The carboxylic acid group at the 3-position serves as a versatile handle for further chemical modifications. Researchers have employed esterification or amidation strategies to enhance water solubility or target specific biological pathways. For instance, esters derived from this compound have demonstrated improved bioavailability in preclinical models when compared to their free acid counterparts. Such modifications underscore the importance of functional group engineering in fine-tuning pharmacological profiles.

Exploring metal-binding properties has emerged as another area of interest for 1H,4H,5H,6H,7H,8H,9H-cyclooctacpyrazole-3-carboxylic acid derivatives. The pyrazole rings act as ligands capable of coordinating with transition metals such as copper and zinc—elements known to play critical roles in enzymatic processes and cellular signaling. Metal complexes formed with this scaffold have shown enhanced stability and altered bioactivity compared to free ligands. These findings open up possibilities for developing metallodrugs targeting metal-dependent diseases or enhancing anticancer therapies.

The compound's compatibility with green chemistry principles has also been noted in recent literature. Solvent-free reactions and catalytic methods have been successfully applied to synthesize derivatives of 1H,4 H ,5 H ,6 H ,7 H ,8 H ,9 H -cyclooctacpyrazole-3-carboxylic acid, reducing environmental impact while maintaining high yields. Such sustainable approaches are increasingly favored in industrial-scale pharmaceutical production where cost efficiency and ecological responsibility go hand-in-hand.

Future directions in research may focus on exploring the compound's potential as a prodrug—a precursor that releases active metabolites inside the body after administration. The cycloalkylpyrazole structure provides an ideal backbone for such transformations due to its ability to undergo metabolic cleavage into smaller pharmacologically active units without generating toxic intermediates.

In conclusion,1 H ,4 H ,5 H ,6 H ,7 H ,8 H ,9 H -cyc looctacpyrazole-3-carboxylic acid (CAS No. 650603-96-6) represents a structurally intriguing molecule with broad applicability in medicinal chemistry and drug development. Its unique combination of steric constraints from the cyclooctane ring and hydrogen bonding capabilities from pyrazole moieties makes it a valuable scaffold for designing next-generation therapeutics targeting inflammation,multitarget diseases,and metal-dependent disorders. Ongoing investigations continue to uncover novel synthetic routes,biochemical functions,and formulation strategies that promise further advancements in its utility within pharmaceutical applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)